ArticleFrontiers in immunology2026
Electroacupuncture at LI11 and SP10 is associated with alleviation of acute urticaria-like reactions in passive cutaneous anaphylaxis: an exploratory analysis of complement-related proteins and multiscale omics.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The lifetime prevalence of acute urticaria is approximately 20%. Although electroacupuncture (EA) has been investigated as an adjunctive treatment for urticaria, the molecular mechanisms underlying these effects remain elusive. Passive cutaneous anaphylaxis (PCA) serves as an experimental model of localized acute IgE-mediated hypersensitivity in the skin, and it recapitulates the key phenotypic characteristics of acute urticaria. In this study, we leverage an ovalbumin (OVA)-induced PCA model to characterize molecular alterations in the skin and serum following EA intervention at LI11 and SP10 using integrative proteomic and metabolomic analyses. Methods: An acute urticaria-like model was established via OVA-induced PCA. Rats were treated at the relevant acupoints for 5 consecutive days, during which the blue wheal areas and scratching frequencies were recorded. Immunoassays (ELISA and immunohistochemistry) and histological staining (H&E and toluidine blue) were used to assess cutaneous pathological alterations, vascular permeability, and inflammatory status. Proteomic and metabolomic analyses were conducted on skin and serum samples from three experimental groups to identify differentially expressed proteins and metabolites. An integrative analysis of the omics data was then conducted to explore potential molecular indicators associated with this intervention at both the protein and metabolite levels. Results: In the acute PCA model, the treatment was concurrent with reduced wheal areas, decreased scratching frequencies, and diminished cutaneous vascular permeabilities. These results suggested attenuated acute inflammatory responses. Multi-omics profiling revealed alterations in the lipid and amino acid metabolic pathways linked to this intervention. The western blot and ELISA results indicated that this intervention coincided with the decreased expression of C3a/C5a and their receptors (C3aR/C5aR) in skin tissues, as well as reduced serum levels of inflammatory mediators (IL-6, TNF-α, and 5-HT). Conclusions: The results of our study indicated that in the OVA-induced PCA model, this intervention was associated with decreased expression of components of the C3a/C5a-C3aR/C5aR axis and alterations in metabolic profiles. These exploratory findings may inform future mechanistic studies of complement and metabolism associations in this acute model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.